Vivo Capital | Healthcare Focused Investment Firm
  • About
    • Ecosystem Approach
    • Our Team
  • Investment Strategy
  • Portfolio
  • News
  • Contact
  • Investor Login

NEWS

All News

  • Portfolio
  • Vivo
  • GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bn

    GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bn

    GlaxoSmithKline plc (LSE/NYSE: GSK) and Sierra Oncology, Inc (Nasdaq: SRRA) today announced that the companies have entered into an agreement under which GSK will acquire Sierra Oncology, a California-based, late-stage biopharmaceutical company focused on targeted…

    READ MORE >>

    April 13, 2022
  • Legend Biotech Announces FDA Approval of CARVYKTI

    Legend Biotech Announces FDA Approval of CARVYKTI

    Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved its first…

    READ MORE >>

    February 28, 2022
  • Lepu Biotech (LEPU biopharma Co., Ltd. ) Announces Pricing of Public Offering

    Lepu Biotech (LEPU biopharma Co., Ltd. ) Announces Pricing of Public Offering

    The biopharmaceutical company focusing on oncology therapeutics – Lepu Biopharma Co., Ltd. (“Lepu Biopharma” or the “Company”, stock code: 2157.HK), has successfully listed and commenced dealings on the Main Board of the Stock Exchange of…

    READ MORE >>

    February 22, 2022
  • UCB and Zogenix (NASDAQ: ZGNX) announced that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases.

    UCB and Zogenix (NASDAQ: ZGNX) announced that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases.

    UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced today that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare…

    READ MORE >>

    January 19, 2022
<< Previous
1 … 5 6 7
  • ESG
  • Privacy Policy

Vivo Capital®, SEC registered, effective 6/19/2014. All rights reserved.

Dear investors, Vivo Capital has transitioned to a new investor portal – Dynamo. The activation email was sent to you earlier. Please contact us if you have any questions.